The FDA approved subcutaneous daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib (Velcade), ...
The investigational oral therapy KTX-1001, also known as gintemetostat, is catching interest as a potential treatment for a subgroup of patients with multiple myeloma, as an expert explained in a ...
In certain cases, regulators will now be open to clearing therapies based on their ability to eliminate tumor cells, a change ...
(Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced the publication of results from a prior Phase 2 clinical study evaluating ...
The FDA has granted fast track designation to LBL-034 for patients with relapsed or refractory multiple myeloma. The U.S.
Data-driven analysis shows outpatient stem-cell mobilisation can reduce hospital bed use while maintaining safety, supported ...
TARPON SPRINGS, Fla., April 25, 2025 -- Allarity Therapeutics, Inc. (ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT ...
Hans Lee, MD, MD Anderson Cancer Center, talks about recent advancements in multiple myeloma treatment pathways. At a recent Institute for Value-Based Medicine ® event in Houston, Hans Lee, MD, ...
A new study conducted by researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore has uncovered a key mechanism behind lenalidomide resistance ...
Real world data show multiple myeloma survival varies by treatment line and autologous stem cell transplant status. Read more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results